Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the fast-growing diabetes and obesity market currently dominated by the likes of Novo Nordisk and Eli Lilly.
Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that complement existing therapy areas, as the company shifts to a 'consolidate' phase with a strong emphasis on improving capacity utilisation, expanding margins, and driving return on capital employed.
Biocon aims to become the world's leading insulin company, capitalising on larger pharmaceutical rivals' strategic shift towards newer, high-margin GLP-1 diabetes therapies. The company plans to expand its insulin presence across 80 markets, focusing on value maximisation and addressing the indispensable need for insulin, particularly for Type-1 and late-stage Type-2 diabetics.
Preferential equity listings in India reached an unprecedented 1,307 in FY26, marking a 33% increase from the previous year and reflecting a strategic choice for companies during market volatility.
Biocon chief Kiran Mazumdar-Shaw met with Karnataka's Chief Minister and Deputy Chief Minister on Diwali, amidst ongoing concerns about Bengaluru's infrastructure.
Mazumdar-Shaw left open whether Biocon will go in for a higher stake or will completely take over the company, which is located near Frankfurt and specialises in manufacturing and marketing a unique range of its own patent-free medicines as well as low-cost drugs from Europan Union nations.
'We do not need short-term measures but long-term ones. Companies seem to have given up on the infrastructure part. Long delays are fuelling more traffic crisis.'
Indian biotech firm Biocon has been featured amongst the top 25 global biotehnology companies according to a report released by Med Ad News.
Meanwhile, Biocon Ltd has received approvals from the Drug Controller General of India to market Abraxane (nanoparticles based, albumin bound paclitaxel) in India.
The CBI has arrested Joint Drugs Controller S Eswara Reddy for allegedly receiving a Rs 4 lakh bribe to waive the phase three clinical trial of the Insulin Aspart injection, a product of Biocon Biologics under development to manage Type 1 and Type 2 diabetes, officials said on Tuesday. Biocon Biologics is a subsidiary of the Kiran Mazumdar Shaw-led Biocon. The company has denied allegations. The agency has also arrested Dinesh Dua, director at Synergy Network India Private Limited, who was allegedly giving Reddy a bribe, they said.
At the meeting of the Board of Governors of IIM Bengaluru held on February 11, the chairperson, Mukesh D Ambani, expressed his decision to step down, IIM-B said.
Given the gestation period for regulatory clearances it is not possible to share any definite timelines.
'We recently launched Yesintek in the immunology space.'
Raising overseas debt has become prohibitively expensive due to the depreciating rupee.
On her first visit to any state in the Indian Union after being sworn in as President of the Republic, Rashtrapati Droupadi Murmu was felicitated in Bengaluru by some of that city's luminaries.
Roche said the Indian regulatory authorities had approved Biocon and Mylan's products as Trastuzumab, but it was unclear if these met the criteria for biosimilar products.
In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.
Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.
The entrepreneur reveals interesting nuggets about her life and career.
Leading stock exchange NSE has tweaked the constituents of its major indices with Adani Group's two companies -- Adani Wilmar and Adani Power -- all set to make their way into some of the Nifty indices from March 31, 2023. Adani Wilmar will be part of Nifty Next 50 and Nifty 100 indices, while Adani Power will be included in Nifty 500, Nifty 200, Nifty Midcap 100, Nifty Midcap 150, Nifty LargeMidcap 250, and Nifty Midsmallcap 400 indices. All the changes in the indices will be effective from March 31 this year, the exchange said in a late night statement on Friday.
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
'Focus on 19,400/64,900 as the key resistance levels for the Nifty/Sensex.'
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
'Kindly advise about the following stocks. Can I hold or exit?'
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Industry leaders, including Mahindra Group chairman Anand Mahindra, RPG Enterprises chairman Harsh Goenka and Biocon Ltd chairperson Kiran Mazumdar-Shaw on Monday came out in support of the Agnipath scheme, saying it has large potential for employment of youth in the corporate sector. Mahindra also expressed dismay over the violence against the scheme while asserting that the farm equipment to aerospace conglomerate welcomes the opportunity to recruit trained, capable and young people under the programme. The Agnipath scheme, announced on June 14, provides for the recruitment of youths between the age bracket of 17-and-half years to 21 for only four years with a provision to retain 25 per cent of them for 15 more years.
Addressing a press briefing, health ministry Joint Secretary Lav Agarwal said currently there are no approved therapies for COVID-19 and there is not enough evidence to claim that plasma therapy can be used for treatment of the disease.
Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
US, China and Japan have no quotas for women and have had the lowest increase in female directors.
Of the total scrips traded, 1,998 advanced, 631 declined and 184 remained unchanged.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
In this second part - of 'Glass-ceiling in India' - we bring you India's successful entrepreneurs. These women are stereotype-busters in their own right.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
Start-ups are adding value to the day-to-day lives of Indian women
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
Domestic pharma giant Ranbaxy Laboratories Limited has topped the list of patent filers in the area of drug applications from the Third World countries last year with 64 new formulations.\n\n\n\n
Kiran Mazumdar-Shaw points out how the adoption of information and communication technologies can provide India with a very effective health care tool.
